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Abstract
The aim of this study was to establish the possible effect of glucocorticoid treatment on upper limb function in a cohort of 91 non-ambulant
DMD boys and adults of age between 11 and 26 years.
All 91 were assessed using the Performance of Upper Limb test. Forty-eight were still on glucocorticoid after loss of ambulation, 25 stopped
steroids at the time they lost ambulation and 18 were GC naïve or had steroids while ambulant for less than a year.
At baseline the total scores ranged between 0 and 74 (mean 41.20). The mean total scores were 47.92 in the glucocorticoid group, 36 in those
who stopped at loss of ambulation and 30.5 in the naïve group (p < 0.001).
The 12-month changes ranged between −20 and 4 (mean −4.4).Themean changes were −3.79 in the glucocorticoid group, −5.52 in those who stopped
at loss of ambulation and −4.44 in the naïve group. This was more obvious in the patients between 12 and 18 years and at shoulder and elbow levels.
Our findings suggest that continuing glucocorticoids throughout teenage years and adulthood after loss of ambulation appears to have a
beneficial effect on upper limb function.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Duchenne muscular dystrophy (DMD) is a progressive
X-linked neuromuscular disease, affecting 1 in 3600 live male
births. Classically untreated boys lose ambulation by 9.5 years
(range 6–12), with respiratory, cardiac and orthopedic
complications following in the second decade and premature
death. Recent studies have, however, demonstrated that there is
a ‘new natural history’ of the disease [1–3], mainly related to
improvements in standards of care [1,4,5], and glucocorticoid
(GC) treatment. The effect of GC has also been confirmed by
Cochrane reviews concluding that GC treatment should be
considered the gold standard as demonstrated by placebo
controlled studies that are not available for any other treatment
[6]. Recent longitudinal studies have clearly shown a delay in
loss of ambulation in boys treated with GC compared to
untreated boys [1]. The outcome appears to be also related to
the regime of GC with a reported median age at loss of
ambulation of 12 years for boys on intermittent regime and of
14.5 years for those on daily treatment [7].
While in the past GC treatment was often only started at the
time when DMD boys were showing more difficulties in getting
up from the floor or climbing stairs [8], the recently published
standards of care suggest that GC treatment should be started
earlier, ideally between 4 and 6 years [4,5], with some studies
suggesting that GC should be started even before the age of 4
years [9].
There is even less agreement on the time when GC treatment
should be discontinued. For many years in several centers the
treatment was discontinued at the time boys lost ambulation as
it was felt that the risk of gaining weight in patients who were
less active was bigger than the possible beneficial effects. A few
recent studies, however, have reported a possible beneficial
effect of GC [1], but no systematic study has been performed
using a scale assessing functional abilities. This is probably also
related to the paucity of clinical tools assessing upper limb
function in DMD [10].
The Performance of Upper Limb (PUL) test, recently
developed as part of an international effort to provide a disease
specific assessment for upper limb function in DMD, has
proved to be a reliable tool, also suitable in a multicentric
setting, for both ambulant and non-ambulant DMD boys and
young adults [11,12]. The PUL allows to follow the proximal
to distal progression of involvement observed in DMD by
assessing various functional abilities in three domains
(shoulder, elbow, distal).
The aim of this study was to establish the possible effect of
GC treatment on upper limb function by using the PUL in a
cohort of non-ambulant DMD boys and adults.
2. Patients and methods
2.1. Patients
The patients included in this study are part of a larger
prospective longitudinal study aimed at assessing upper limb
function in a larger cohort of ambulant and non-ambulant DMD
boys and adults involving 13 tertiary neuromuscular centers.
Preliminary cross sectional data of the study at baseline have
already been reported [11]. The previous study also reports
inter rater reliability. All clinical evaluators were trained by
the same lead physical therapist to ensure standardization
of equipment, assessment procedures and scoring.The study
has been approved by the Ethic Committee of each center.
Informed consent was obtained from each patient.
As we aimed to establish the possible effect of GC in patients
who maintained it after loss of ambulation compared to those
who stopped GC at the time when they lost ambulation, in this
study we only included non-ambulant patients who had lost
ambulation for at least two years. Patients were retrospectively
subdivided into three subgroups: a) those who were still on GC
after loss of ambulation, b) those who stopped GC at the time
they lost ambulation; c) those who were never on GC or who
had them while ambulant for less than a year. In order to make
the groups comparable we did not include 4 patients above the
age of 26 years as they were all untreated.
2.2. PUL
The PUL includes 22 items with an entry item to define the
starting functional level, and 21 items subdivided into shoulder
level (4 items), middle level (9 items) and distal level (8 items)
dimensions. For weaker patients a low score on the entry item
means high-level items do not need to be performed. Scoring
options vary across the scale between 0–1 and 0–6 according to
performance. Each dimension can be scored separately with a
maximum score of 16 for the shoulder level, 34 for the middle
level, and 24 for the distal level [11]. A total score can be
achieved by adding the three level scores (max total score 74).
2.3. Statistical analysis
Baseline PUL was compared across the 3 GC groups
adjusting for age using a global test based on a repeated
measures ANOVA, considering shoulder, middle and distal
PUL assessments as repeated measures on the same subject,
with age (<18 and ≥18 years) and GC subgroups as factors. This
global test approach gives a unique p value for a difference
across GC subgroups of PUL assessments. Post-hoc
comparisons using an ANOVA model were run separately for
assessing the impact of age and GC subgroup on shoulder,
middle and distal assessments.
Twelve-month change was evaluated as a % decrease from
baseline; patients with PUL = 0 at baseline were excluded from
the analysis of change; patients with a PUL increase over 12
months were set as stable patients (decrease = 0). Differences
among 12-month changes were assessed by the non-parametric
Kruskal–Wallis test.
3. Results
Ninety-one patients fulfilled the inclusion criteria. Their age
ranged between 11.1 and 26.9 years (mean 16.95; SD ± 3.52).
Forty-eight were still on GC: 7 of the 48 were on daily steroids
(mean dose 0.45 mg/kg/day) and 41 on intermittent (mean dose
0.49 mg/kg/day). Another 25 patients stopped GC at the time
when they lost ambulation. The mean age when they stopped
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ambulation between the two subgroups was similar (11.2 and
11.1 years respectively).
The remaining 18 were GC naïve or had GC while ambulant
for less than a year.
3.1. PUL
The total scores ranged between 0 and 74 at baseline (mean
41.20).
The mean total scores were 47.92 in the GC group, 36 in
those who stopped GC at loss of ambulation and 30.5 in the GC
naïve group (Table 1).
Baseline PUL significantly increased passing from shoulder
(mean = 1.85) to middle (mean = 19.14) to distal (mean = 20.21,
p < 0.01) domains (Fig. 1 and Table 1). Baseline PUL was
significantly higher in those who never stopped GC than in
those who stopped GC or never used GC (global test p < 0.001)
and was lower in patients with age higher than 18 years (global
test, p < 0.001).
While in the shoulder PUL was close to zero for all the
patients (71% in those who never stopped, 80% in those who
stopped and 100% in those who never used GC, p = 0.006),
the difference was very evident in the middle region (mean in
those who never stopped = 24.02, mean in those who
stopped = 15.20 and mean in those who never used GC = 11.61,
p < 0.001). The trend is still present in the distal PUL that is
less affected (mean in those who never stopped = 21.17, mean
in those who stopped = 19.32 and mean in those who never
used GC = 18.89, p = 0.04). These differences were significant
also adjusting for age.
Overall, shoulder PUL was = 0 in 79% of patients, while
middle PUL was = 0 in 4 (4%) patients and distal PUL was
higher than 0 in all the patients. Therefore 12-month PUL
change was evaluated only in the middle and distal regions. The
percentage decrease in the middle PUL was −10% in patients
still using GC as compared to −34% and −36% in those who
stopped and never used GC respectively (p < 0.001). The
change was lower (mean = −4.5%) and not significantly
different among the GC groups in the distal region (p = 0.77).
The 12-month changes ranged between −20 and 4 (mean
−4.4). The mean changes were −3.79 in the GC group, −5.52 in
those who stopped GC at loss of ambulation and −4.44 in the
GC naïve group.
Table 1
Baseline values according to age and GC exposure for total PUL score and the three domains.
AGE Baseline S Baseline M Baseline D Baseline T
Still using Mean 16.98 2.73 24.02 21.17 47.92
(n = 48) SD 3.873 4.911 10.245 3.738 16.240
All Stopped Mean 16.21 1.48 15.20 19.32 36.00
(n = 25) SD 3.060 3.664 11.475 4.828 18.118
Naïve Mean 18.03 .00 11.61 18.89 30.50
(n = 18) SD 3.050 .000 9.971 2.632 11.927
Total Mean 16.98 1.85 19.14 20.21 41.20
(n = 91) SD 3.532 4.160 11.707 3.985 17.510
Still using Mean 14.77 3.88 25.61 21.61 51.09
(n = 33) SD 1.652 5.550 9.083 3.122 15.277
<18 yrs Stopped Mean 14.94 1.95 18.68 20.68 41.32
(n = 19) SD 1.898 4.116 10.630 3.728 16.783
Naïve Mean 15.43 .00 15.11 20.00 35.11
(n = 9) SD 1.590 .000 11.152 2.121 12.494
Total Mean 14.92 2.70 21.90 21.08 45.69
(n = 61) SD 1.710 4.852 10.594 3.216 16.392
Still using Mean 21.84 .20 20.53 20.20 40.93
(n = 15) SD 2.703 .775 12.035 4.814 16.611
>18 yrs Stopped Mean 20.21 .00 4.17 15.00 19.17
(n = 6) SD 2.577 .000 5.742 5.692 10.685
Naïve Mean 20.64 .00 8.11 17.78 25.89
(n = 9) SD 1.402 .000 7.705 2.728 9.918
Total Mean 21.16 .10 13.53 18.43 32.07
(n = 30) SD 2.393 .548 12.025 4.797 16.339
Fig. 1. Baseline PUL scores in the shoulder (S), middle (M) and distal (D)
domains, according to GC exposure.
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Table 2 and Fig. 2 show details of the changes in the whole
cohort and in the subgroups subdivided according to GC
treatment.
4. Discussion
The issue of continuing GC treatment after loss of ambulation
has not yet reached a full consensus with, until recently, relative
lack of available information on efficacy and safety data from the
literature. This is also acknowledged by the DMD care guidelines
published in 2010 that identify the use of GC therapy in
non-ambulatory individuals as an area in need of further research.
In the last few years a few studies have provided more evidence of
the efficacy of GC treatment on cardiac [13] and respiratory
functions and on strength and other functionalmeasures [1,14], but
many clinicians still feel that there is not enough evidence to justify
the use of GC after loss of ambulation. This is mainly due to the
concern that the side effect such as increased weight gain
following a reduction of physical activity secondary to loss of
ambulation may outweigh the possible beneficial effect.
Our results, using the PUL, a tool specifically developed to
assess upper limb function in DMD, suggest that GC has a
beneficial effect on upper limb function after loss of
ambulation. The GC treated group had an overall better baseline
function than the untreated ones. Not surprisingly those who
had been on GC until loss of ambulation had better baseline
scores than the GC naïve group. The overall difference was
more obvious on the middle domain with GC treated patients
having significantly higher scores than in the other groups,
especially between the age of 12 and 18 years. In this age range
most GC treated patients were still able to perform most of the
activities exploring functional aspects from the elbow and also
had some functional activities at shoulder level that were less
present in those who stopped GC steroids at loss of ambulation
and even less in the GC naïve group. This trend was confirmed,
even if to a lesser extent, also in the patients older than 18 years.
The difference between the GC treated and untreated groups
was also obvious in the 12-month changes as the treated group
had a slightly slower deterioration than the untreated ones. This
again was most obvious in the middle domain and between 12
and 18 years. In contrast at shoulder level the treated group
appeared to have more negative changes compared to the
untreated ones. This is, however, only due to the fact that the
Table 2
12-month changes according to age and GC exposure for total PUL score and the three domains.
AGE 12-month changes S 12-month changes M 12-month changes D 12-month changes T
Still using Mean 16.98 −1 −2.06 −0.73 −3.79
(n = 48) SD 3.873 2.51 3.04 1.63 3.71
All Stopped Mean 16.21 −0.08 −4.60 −0.84 −5.52
(n = 25) SD 3.060 1.25 6.30 1.40 7.08
Naïve Mean 18.03 0 −3.83 −0.61 −4.44
(n = 18) SD 3.050 0 4.16 1.37 4.63
Total Mean 16.98 −0.55 −3.11 −0.74 −4.4
(n = 91) SD 3.532 1.99 4.47 1.51 5
Still using Mean 14.77 −1.36 −2.09 −0.64 −4.09
(n = 33) SD 1.652 2.93 2.91 1.49 3.76
<18 Stopped Mean 14.94 −0.11 −5.84 −1.00 −6.95
(n = 19) SD 1.898 1.44 6.74 1.41 7.38
Naïve Mean 15.43 .00 −4.11 −0.89 −5
(n = 9) SD 1.590 .000 4.42 1.83 4.71
Total Mean 14.92 −0.77 −3.56 −0.79 −5.11
(n = 61) SD 1.710 2.37 4.86 1.50 5.34
Still using Mean 21.84 −2.20 −2.00 −0.93 −3.13
(n = 15) SD 2.703 0.77 3.42 1.94 3.66
>18 Stopped Mean 20.21 .00 −0.67 -0.33 −1.00
(n = 6) SD 2.577 .000 1.63 1.36 2.96
Naïve Mean 20.64 .00 −3.50 −0.10 −3.60
(n = 9) SD 1.402 .000 3.89 0.99 4.57










Fig. 2. Middle and distal 12-month PUL change decrease (%) according to GC
exposure in the middle domain (in green) and in the distal domain (in blue).
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treated group had better baseline shoulder subscores and was
therefore more likely to lose points related to the residual
shoulder activity while the untreated groups had much lower
baseline shoulder subscores (0 in the naïve group) and therefore
were more unlikely to lose any further point.
The PUL did not appear to be equally sensitive to capture the
differences in the distal domain as most of the items in the distal
domain assessing very distal activities such as different pinches
were still present even in the older untreated boys.
One of the limitations of this study is that the results in the
non-ambulant cohort were part of a larger study also including
ambulant boys, and the study was not prospectively designed with
a randomized approach to establish the value of different regimens
of GC. Even if patients were not prospectively randomized,
however, there were no obvious differences in age between the two
main groups. The mean ages of the patients who were still on
steroids and those who stopped at loss of ambulation were similar,
or if anything the latter were even slightly older. The ages when
they stopped ambulation were also similar.
Our data provide for the first time evidence that continuing
GC after loss of ambulation had a beneficial effect on upper
limb function even if most patients were on an intermittent
regime and on a relatively low dose as after loss of ambulation
the dose is often not adapted to the weight.
The effect of GC was more obvious in the patients between
12 and 18 years and at shoulder and elbow levels. This issue is
highly relevant if we consider that the activities assessed at
middle domain include activities that are essential for
functional activities such as self-feeding or ability to perform
positional transfers. Maintaining these activities or slowing the
progression leading to their loss is therefore likely to have a
significant impact on their activities of daily living and on their
overall quality of life. Further studies, using a more systematic
prospective approach, will help to clarify the possible effects of
different regime steroids or dosage or weight that were not
systematically explored in our study.
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